Who Paid My Doc
Hari Baddigam
Panama City, FL Medical Doctor
NPI 1881629491 CMS profile 357413
801 E 6Th St, Suite 504, Panama City, FL 32401
General payments
$15,376
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Hari Baddigam of Panama City, FL is reported in the CMS Open Payments database as having received $15,376 across 208 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $680 | 35 | |
| 2024 | General | $572 | 19 | |
| 2023 | General | $3,922 | 41 | |
| 2022 | General | $1,727 | 14 | |
| 2021 | General | $1,786 | 13 | |
| 2020 | General | $2,492 | 33 | |
| 2019 | General | $4,197 | 53 |
Beside peers
- Hari Baddigam
- Florida median
- Middle half of Florida
- National median
In program year 2025, general payments to Hari Baddigam were reported at $680. Among 84,641 Florida profiles paid that year, the median was $195 and the middle half received between $59 and $690.
Show as a table
| Year | Hari Baddigam | Florida median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $4,197 | $197 | $63–$719 | $163 |
| 2020 | $2,492 | $126 | $38–$436 | $114 |
| 2021 | $1,786 | $151 | $45–$537 | $132 |
| 2022 | $1,727 | $175 | $53–$607 | $149 |
| 2023 | $3,922 | $183 | $57–$637 | $160 |
| 2024 | $572 | $185 | $56–$647 | $164 |
| 2025 | $680 | $195 | $59–$690 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 22 drugsPart D claims
823
Drug cost
$195,823
Branded share of claims
37.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Eliquis Apixaban | Brand | 102 | $111,556 | |
| Xarelto Rivaroxaban | Brand | 20 | $26,513 | |
| Entresto Sacubitril/Valsartan | Brand | 19 | $25,453 | |
| Multaq Dronedarone Hcl | Brand | 11 | $20,376 | |
| Ranolazine Er Ranolazine | Brand | 27 | $2,260 | |
| Amiodarone Hcl | Generic | 25 | $1,708 | |
| Nebivolol Hcl | Generic | 17 | $1,287 | |
| Digoxin | Generic | 30 | $887 | |
| Doxazosin Mesylate | Generic | 73 | $765 | |
| Diltiazem 24hr Er (Cd) Diltiazem Hcl | Brand | 41 | $732 |
The 10 drugs with the highest cost, of 22 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 65 billing codesPaid by Medicare
$585,797
Medicare patients
1,079
Services billed
8,091
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 60% | |
| Ischemic heart disease | 46% | |
| Heart failure | 41% | |
| Diabetes | 39% | |
| Atrial fibrillation | 38% | |
| COPD | 30% | |
| Chronic kidney disease | 29% |
| Drug given in the clinic | Where | Patients | Services | Paid by Medicare |
|---|---|---|---|---|
| Injection, regadenoson, 0.1 mg J2785 | Office | 55 | 221 | $645 |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
208 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.